Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
10,154
archived clinical trials in
Other Indications

Pharmacokinetic Response to BPI in Burns
Phase IIa Trial to Evaluate the Pharmacokinetic Response to Bactericidal/Permeability-Increasing Protein (rBPI21) for the Treatment of Patients With Burn Injury.
Status: Enrolling
Updated:  6/2/2008
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Pharmacokinetic Response to BPI in Burns
Phase IIa Trial to Evaluate the Pharmacokinetic Response to Bactericidal/Permeability-Increasing Protein (rBPI21) for the Treatment of Patients With Burn Injury.
Status: Enrolling
Updated: 6/2/2008
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Initial Versus Delayed Operation for Treatment of Complicated Appendicitis In Children
Initial Versus Delayed Operation for Treatment of Complicated Appendicitis In Children
Status: Enrolling
Updated:  6/3/2008
Mott Childrens Hospital
mi
from
Ann Arbor, MI
Initial Versus Delayed Operation for Treatment of Complicated Appendicitis In Children
Initial Versus Delayed Operation for Treatment of Complicated Appendicitis In Children
Status: Enrolling
Updated: 6/3/2008
Mott Childrens Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Tranexamic Acid for Craniofacial Surgery
Tranexamic Acid for the Reduction of Allogeneic Blood Exposure in Infants and Children Having Craniofacial Surgery
Status: Enrolling
Updated:  7/24/2008
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Tranexamic Acid for Craniofacial Surgery
Tranexamic Acid for the Reduction of Allogeneic Blood Exposure in Infants and Children Having Craniofacial Surgery
Status: Enrolling
Updated: 7/24/2008
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Multi Cervical Unit Measures of Cervical Isometric Strength and Range of Motion: A Pilot Study
Status: Enrolling
Updated:  10/16/2008
Logan University, College of Chiropractic
mi
from
Chesterfield, MO
Multi Cervical Unit Measures of Cervical Isometric Strength and Range of Motion: A Pilot Study
Status: Enrolling
Updated: 10/16/2008
Logan University, College of Chiropractic
mi
from
Chesterfield, MO
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
Child Neurology Associates, PC
mi
from
Little Rock, AR
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
Child Neurology Associates, PC
mi
from
Little Rock, AR
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
Midwest Children's Health Research Institute
mi
from
Los Angeles, CA
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
Midwest Children's Health Research Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
University of California, Irvine Medical Center
mi
from
Orange, CA
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
University of California, Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
UCSD Pediatric Pharmacology Research Unit
mi
from
San Diego, CA
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
UCSD Pediatric Pharmacology Research Unit
mi
from
San Diego, CA
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
Rocky Mountain Pediatrics, PC
mi
from
Lakewood, CO
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
Rocky Mountain Pediatrics, PC
mi
from
Lakewood, CO
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
Neufeld Medical Group, Inc.
mi
from
Fort Myers, FL
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
Neufeld Medical Group, Inc.
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
Miami Children's Hospital
mi
from
Miami, FL
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
Miami Children's Hospital
mi
from
Miami, FL
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
Miami Children's Hospital - Medical Genetics and Neuro-Developmental Center
mi
from
Miami, FL
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
Miami Children's Hospital - Medical Genetics and Neuro-Developmental Center
mi
from
Miami, FL
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
Phoenix Children's Hospital
mi
from
Miami, FL
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
Phoenix Children's Hospital
mi
from
Miami, FL
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
Clinical Studies Centers, LLC
mi
from
St. Petersburg, FL
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
Clinical Studies Centers, LLC
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
Northwest Clinical Research Center
mi
from
West Palm Beach, FL
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
Northwest Clinical Research Center
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
Road Runner Research
mi
from
Atlanta, GA
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
Road Runner Research
mi
from
Atlanta, GA
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
Hurley Medical Center
mi
from
Flint, MI
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
Hurley Medical Center
mi
from
Flint, MI
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
Saint Mary's Health Care
mi
from
Grand Rapids, MI
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
Saint Mary's Health Care
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
Washington University School of Medicine
mi
from
Grand Rapids, MI
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
Washington University School of Medicine
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
Regions Hospital
mi
from
Saint Paul, MN
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
Regions Hospital
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
Northwest Clinical Research Center
mi
from
Saint Louis, MO
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
Northwest Clinical Research Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
Meridien Research
mi
from
Lincoln, NE
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
Meridien Research
mi
from
Lincoln, NE
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
Clinical Research Center of New Jersey
mi
from
Voorhees, NJ
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
Clinical Research Center of New Jersey
mi
from
Voorhees, NJ
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
Division of Genetics and Developmental Behavior
mi
from
Durham, NC
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
Division of Genetics and Developmental Behavior
mi
from
Durham, NC
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
MetroHealth Med Ctr
mi
from
Cleveland, OH
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
Valko and Associates
mi
from
Toledo, OH
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
Valko and Associates
mi
from
Toledo, OH
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
Office of Lazlo Mate
mi
from
Tulsa, OK
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
Office of Lazlo Mate
mi
from
Tulsa, OK
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
Medical University of South Carolina
mi
from
Charleston, SC
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
Vanderbilt Children's Hospital
mi
from
Nashville, TN
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
Vanderbilt Children's Hospital
mi
from
Nashville, TN
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
Down Syndrome Clinic of Houston
mi
from
Houston, TX
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
Down Syndrome Clinic of Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
Alamo City Clinical Research, LLC
mi
from
San Antonio, TX
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
Alamo City Clinical Research, LLC
mi
from
San Antonio, TX
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
Community Research Foundation
mi
from
San Antonio, TX
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
Community Research Foundation
mi
from
San Antonio, TX
Click here to add this to my saved trials
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  12/10/2008
Neuropsychiatric Research Center of Southwest Florida
mi
from
Bellevue, WA
Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 12/10/2008
Neuropsychiatric Research Center of Southwest Florida
mi
from
Bellevue, WA
Click here to add this to my saved trials
Vitamin D Levels in Children Undergoing Adenotonsillectomies and Controls
Vitamin D Levels in Children Undergoing Adenotonsillectomies and Controls
Status: Enrolling
Updated:  1/26/2009
University of Chicago
mi
from
Chicago, IL
Vitamin D Levels in Children Undergoing Adenotonsillectomies and Controls
Vitamin D Levels in Children Undergoing Adenotonsillectomies and Controls
Status: Enrolling
Updated: 1/26/2009
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Non-Rhinologic Etiologies of Headaches and Facial Pain in Tertiary Care Setting
Non-Rhinologic Etiologies of Headaches and Facial Pain in Tertiary Care Setting
Status: Enrolling
Updated:  2/3/2009
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Non-Rhinologic Etiologies of Headaches and Facial Pain in Tertiary Care Setting
Non-Rhinologic Etiologies of Headaches and Facial Pain in Tertiary Care Setting
Status: Enrolling
Updated: 2/3/2009
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Glycemic Effects of Morning Only, Evening Only or Twice Daily Insulin Glargine in Patients With Type 1 Diabetes
Comparison of Glycemic Response to Morning Only, Evening Only or Twice Daily Insulin Glargine in Patients With Type 1 Diabetes Using Continuous Glucose Monitoring
Status: Enrolling
Updated:  3/25/2009
Johns Hopkins Hospital
mi
from
Baltimore, MD
Glycemic Effects of Morning Only, Evening Only or Twice Daily Insulin Glargine in Patients With Type 1 Diabetes
Comparison of Glycemic Response to Morning Only, Evening Only or Twice Daily Insulin Glargine in Patients With Type 1 Diabetes Using Continuous Glucose Monitoring
Status: Enrolling
Updated: 3/25/2009
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Initiating Transdermal Estradiol Therapy in Turner's Syndrome
Initiating Transdermal Estradiol Therapy in Turner's Syndrome
Status: Enrolling
Updated:  4/9/2009
University of Chicago
mi
from
Chicago, IL
Initiating Transdermal Estradiol Therapy in Turner's Syndrome
Initiating Transdermal Estradiol Therapy in Turner's Syndrome
Status: Enrolling
Updated: 4/9/2009
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Initiating Transdermal Estradiol Therapy in Turner's Syndrome
Initiating Transdermal Estradiol Therapy in Turner's Syndrome
Status: Enrolling
Updated:  4/9/2009
John Hopkins University
mi
from
Lutherville, MD
Initiating Transdermal Estradiol Therapy in Turner's Syndrome
Initiating Transdermal Estradiol Therapy in Turner's Syndrome
Status: Enrolling
Updated: 4/9/2009
John Hopkins University
mi
from
Lutherville, MD
Click here to add this to my saved trials
Initiating Transdermal Estradiol Therapy in Turner's Syndrome
Initiating Transdermal Estradiol Therapy in Turner's Syndrome
Status: Enrolling
Updated:  4/9/2009
University of Michigan
mi
from
Ann Arbor, MI
Initiating Transdermal Estradiol Therapy in Turner's Syndrome
Initiating Transdermal Estradiol Therapy in Turner's Syndrome
Status: Enrolling
Updated: 4/9/2009
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Examining Social, Emotional, and Cognitive Functioning in People With Fragile X and Down Syndromes
Genetics and Physiology of Social Anxiety in Fragile X
Status: Enrolling
Updated:  4/10/2009
M.I.N.D. Institute, University of California, Davis
mi
from
Sacramento, CA
Examining Social, Emotional, and Cognitive Functioning in People With Fragile X and Down Syndromes
Genetics and Physiology of Social Anxiety in Fragile X
Status: Enrolling
Updated: 4/10/2009
M.I.N.D. Institute, University of California, Davis
mi
from
Sacramento, CA
Click here to add this to my saved trials
Non-Invasive Determination of Fetal Chromosome Abnormalities
Non-Invasive Determination of Fetal Chromosome Abnormalities
Status: Enrolling
Updated:  4/30/2009
Maryland Perinatal Associates
mi
from
Rockville, MD
Non-Invasive Determination of Fetal Chromosome Abnormalities
Non-Invasive Determination of Fetal Chromosome Abnormalities
Status: Enrolling
Updated: 4/30/2009
Maryland Perinatal Associates
mi
from
Rockville, MD
Click here to add this to my saved trials
Non-Invasive Determination of Fetal Chromosome Abnormalities
Non-Invasive Determination of Fetal Chromosome Abnormalities
Status: Enrolling
Updated:  4/30/2009
Atlantic Maternal Fetal Medicine
mi
from
Moristown, NJ
Non-Invasive Determination of Fetal Chromosome Abnormalities
Non-Invasive Determination of Fetal Chromosome Abnormalities
Status: Enrolling
Updated: 4/30/2009
Atlantic Maternal Fetal Medicine
mi
from
Moristown, NJ
Click here to add this to my saved trials
Non-Invasive Determination of Fetal Chromosome Abnormalities
Non-Invasive Determination of Fetal Chromosome Abnormalities
Status: Enrolling
Updated:  4/30/2009
Winthrop University Hospital
mi
from
Mineola, NY
Non-Invasive Determination of Fetal Chromosome Abnormalities
Non-Invasive Determination of Fetal Chromosome Abnormalities
Status: Enrolling
Updated: 4/30/2009
Winthrop University Hospital
mi
from
Mineola, NY
Click here to add this to my saved trials
Non-Invasive Determination of Fetal Chromosome Abnormalities
Non-Invasive Determination of Fetal Chromosome Abnormalities
Status: Enrolling
Updated:  4/30/2009
Elite Women's Health
mi
from
New Hyde Park, NY
Non-Invasive Determination of Fetal Chromosome Abnormalities
Non-Invasive Determination of Fetal Chromosome Abnormalities
Status: Enrolling
Updated: 4/30/2009
Elite Women's Health
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Non-Invasive Determination of Fetal Chromosome Abnormalities
Non-Invasive Determination of Fetal Chromosome Abnormalities
Status: Enrolling
Updated:  4/30/2009
Columbia University, NewYork-Presbyterian Hospital
mi
from
New York, NY
Non-Invasive Determination of Fetal Chromosome Abnormalities
Non-Invasive Determination of Fetal Chromosome Abnormalities
Status: Enrolling
Updated: 4/30/2009
Columbia University, NewYork-Presbyterian Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Non-Invasive Determination of Fetal Chromosome Abnormalities
Non-Invasive Determination of Fetal Chromosome Abnormalities
Status: Enrolling
Updated:  4/30/2009
New York Perinatal Associates
mi
from
New York, NY
Non-Invasive Determination of Fetal Chromosome Abnormalities
Non-Invasive Determination of Fetal Chromosome Abnormalities
Status: Enrolling
Updated: 4/30/2009
New York Perinatal Associates
mi
from
New York, NY
Click here to add this to my saved trials
Non-Invasive Determination of Fetal Chromosome Abnormalities
Non-Invasive Determination of Fetal Chromosome Abnormalities
Status: Enrolling
Updated:  4/30/2009
UVM
mi
from
Burlington, VT
Non-Invasive Determination of Fetal Chromosome Abnormalities
Non-Invasive Determination of Fetal Chromosome Abnormalities
Status: Enrolling
Updated: 4/30/2009
UVM
mi
from
Burlington, VT
Click here to add this to my saved trials
Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome
A 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome
Status: Enrolling
Updated:  8/4/2009
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome
A 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome
Status: Enrolling
Updated: 8/4/2009
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials